Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better tha

详细信息    查看全文

• 作者：Jae-Sook Ahn ; Hyeoung-Joon Kim ; Yeo-Kyeoung Kim ; Sung-Hoon Jung…
• 关键词：Acute myeloid leukaemia ; FLT3 ; ITD ; NPM1 ; CEBPA ; Allogeneic haematopoietic cell transplantation ; Normal karyotype
• 刊名：Annals of Hematology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：95
• 期：4
• 页码：625-635
• 全文大小：721 KB
• 参考文献：1.Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD, European L (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474. doi:10.​1182/​blood-2009-07-235358 CrossRef PubMed
  2.Sanders MA, Valk PJ (2013) The evolving molecular genetic landscape in acute myeloid leukaemia. Curr Opin Hematol 20(2):79–85. doi:10.​1097/​MOH.​0b013e32835d821c​ CrossRef PubMed
  3.Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A, Ligges S, Sauer T, Tschanter P, Thoennissen GB, Berning B, Kolb HJ, Reichle A, Holler E, Schwerdtfeger R, Arnold R, Scheid C, Muller-Tidow C, Woermann BJ, Hiddemann W, Berdel WE, Buchner T (2014) Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol: Off J Am Soc Clin Oncol 32(4):288–296. doi:10.​1200/​JCO.​2013.​50.​5768 CrossRef
  4.Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96(13):4075–4083PubMed
  5.Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92(7):2322–2333PubMed
  6.Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD, Cancer, Leukemia Group B (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13):4325–4336. doi:10.​1182/​blood-2002-03-0772 CrossRef PubMed
  7.Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Dohner H, German-Austrian Acute Myeloid Leukemia Study G (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358(18):1909–1918. doi:10.​1056/​NEJMoa074306 CrossRef PubMed
  8.Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, Bullinger L, Frohling S, Dohner H (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106(12):3740–3746. doi:10.​1182/​blood-2005-05-2164 CrossRef PubMed
  9.Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107(10):4011–4020. doi:10.​1182/​blood-2005-08-3167 CrossRef PubMed
  10.Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106(12):3733–3739. doi:10.​1182/​blood-2005-06-2248 CrossRef PubMed
  11.Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H, Group A (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100(8):2717–2723CrossRef PubMed
  12.Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol: Off J Am Soc Clin Oncol 26(31):5078–5087. doi:10.​1200/​JCO.​2008.​17.​5554 CrossRef
  13.Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, Lucid C, Vnencak-Jones CL, Greer JP, Savani BN (2012) Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant 47(12):1535–1537. doi:10.​1038/​bmt.​2012.​88 CrossRef PubMed
  14.Martelli MP, Sportoletti P, Tiacci E, Martelli MF, Falini B (2013) Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev 27(1):13–22. doi:10.​1016/​j.​blre.​2012.​11.​001 CrossRef PubMed
  15.Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol: Off J Am Soc Clin Oncol 30(7):735–741. doi:10.​1200/​JCO.​2011.​36.​9868 CrossRef
  16.Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC, Medical Research Council Adult Leukaemia Working P (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5):2776–2784. doi:10.​1182/​blood-2007-08-109090 CrossRef PubMed
  17.Kim YK, Kim HN, Lee SR, Ahn JS, Yang DH, Lee JJ, Lee IK, Shin MG, Kim HJ (2010) Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol 45(1):36–45. doi:10.​5045/​kjh.​2010.​45.​1.​36 CrossRef PubMed PubMedCentral
  18.Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15(6):825–828PubMed
  19.Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 11(12):945–956. doi:10.​1016/​j.​bbmt.​2005.​09.​004 CrossRef
  20.Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. doi:10.​1038/​bmt.​2012.​244 CrossRef PubMed PubMedCentral
  21.Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Dohner H, Antin JH, Soiffer RJ, Cutler C (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301(22):2349–2361. doi:10.​1001/​jama.​2009.​813 CrossRef PubMed PubMedCentral
  22.Brunet S, Martino R, Sierra J (2013) Hematopoietic transplantation for acute myeloid leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD). Curr Opin Oncol 25(2):195–204. doi:10.​1097/​CCO.​0b013e32835ec91f​ CrossRef PubMed
  23.Bornhauser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C, group ASs (2007) Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 109(5):2264–2265. doi:10.​1182/​blood-2006-09-047225 , author reply 2265CrossRef PubMed
  24.DeZern AE, Sung A, Kim S, Smith BD, Karp JE, Gore SD, Jones RJ, Fuchs E, Luznik L, McDevitt M, Levis M (2011) Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant 17(9):1404–1409. doi:10.​1016/​j.​bbmt.​2011.​02.​003 CrossRef
  25.Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Gohring G, Kundgen A, Held G, Gotze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Dohner H, Cornelissen JJ, Dohner K, Lowenberg B (2013) The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 122(9):1576–1582. doi:10.​1182/​blood-2013-05-503847 CrossRef PubMed
  26.Port M, Bottcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L (2014) Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol 93(8):1279–1286. doi:10.​1007/​s00277-014-2072-6 CrossRef PubMed
  27.Pastore F, Kling D, Hoster E, Dufour A, Konstandin NP, Schneider S, Sauerland MC, Berdel WE, Buechner T, Woermann B, Braess J, Hiddemann W, Spiekermann K (2014) Long-term follow-up of cytogenetically normal CEBPA-mutated AML. J Hematol Oncol 7:55. doi:10.​1186/​s13045-014-0055-7 CrossRef PubMed PubMedCentral
  28.Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE (2010) Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol: Off J Am Soc Clin Oncol 28(16):2739–2747. doi:10.​1200/​JCO.​2009.​26.​2501 CrossRef
  29.Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Delwel R, Lowenberg B, Valk PJ (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106(12):3747–3754. doi:10.​1182/​blood-2005-05-2168 CrossRef PubMed
  
• 作者单位：Jae-Sook Ahn (1)
  Hyeoung-Joon Kim (1)
  Yeo-Kyeoung Kim (1)
  Sung-Hoon Jung (1)
  Deok-Hwan Yang (1)
  Je-Jung Lee (1)
  Nan Young Kim (2)
  Seung Hyun Choi (2)
  Chul Won Jung (3)
  Jun-Ho Jang (3)
  Hee Je Kim (4)
  Joon Ho Moon (5)
  Sang Kyun Sohn (5)
  Jong-Ho Won (6)
  Sung-Hyun Kim (7)
  Dennis Dong Hwan Kim (8)
  
  1. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun, Jeollanam-do, 519-763, Republic of Korea
  2. Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea
  3. Division of Hematology-Oncology, Samsung Medical Center, Seoul, South Korea
  4. Department of Hematology, Cancer Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
  5. Department of Hematology-Oncology, Kyungpook National University Hospital, Daegu, South Korea
  6. Department of Hematology-Oncology, Soon Chun Hyang University Hospital, Seoul, South Korea
  7. Department of Hematology-Oncology, Dong-A University College of Medicine, Busan, South Korea
  8. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

The prognostic significance of molecular mutations (FLT3-ITD, NPM1, and CEBPA mutations) was examined in patients with normal-karyotype acute myeloid leukaemia (NK-AML) after allogeneic haematopoietic cell transplantation (HCT). In total, 115 patients received allogeneic HCT for NK-AML and were evaluated for FLT3-ITD, NPM1, and CEBPA mutations in diagnostic samples and for long-term outcomes following HCT, retrospectively. The prevalences of FLT3-ITDpos, NPM1 mut, and CEBPA dm (double mutations) were 32.2, 43.5, and 24.6 %, respectively. The triple-negative group (NPM1 wild/FLT3-ITDneg/non-CEBPA dm) showed a similar transplant outcome to those in the favourable European LeukemiaNet (ELN) risk group for overall survival (OS) (60.9 vs. 63.7 %; p = 0.810), but a more favourable OS than others in the intermediate-I risk group (40.0 %; p = 0.034). Also, the triple-negative group showed a similar relapse rate at 5 years compared with those in the favourable risk group (9.7 vs. 15.5 %; p = 0.499), but a lower rate of relapse than the others in the intermediate-I risk group (15.5 vs. 48.6 %; p = 0.004). The 5-year relapse incidences were 4.0 % (NPM1 mut/FLT3-ITDneg), 14.7 % (CEBPA dm), 15.5 % (NPM1 wild/FLT3-ITDneg/non-CEBPA dm), 39.1 % (NPM1 mut/FLT3-ITDpos/non-CEBPA dm), and 66.7 % (NPM1 wild/FLT3-ITDpos/non-CEBPA dm). Thus, the triple-negative (NPM1 wild/FLT3-ITDneg/non-CEBPA dm) group showed favourable long-term outcomes after allogeneic HCT in NK-AML, similar to those of the favourable risk group by the ELN risk classification.